Dupont Capital Management Corp bought a new position in Boston Scientific Corporation (NYSE:BSX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,798 shares of the medical equipment provider’s stock, valued at approximately $257,000.
Several other hedge funds also recently bought and sold shares of the company. Capital World Investors lifted its holdings in shares of Boston Scientific Corporation by 1.6% in the second quarter. Capital World Investors now owns 101,914,290 shares of the medical equipment provider’s stock worth $2,825,064,000 after acquiring an additional 1,611,442 shares during the last quarter. BlackRock Inc. increased its stake in shares of Boston Scientific Corporation by 4.6% in the second quarter. BlackRock Inc. now owns 100,184,511 shares of the medical equipment provider’s stock valued at $2,777,113,000 after buying an additional 4,439,966 shares during the period. Vanguard Group Inc. increased its stake in shares of Boston Scientific Corporation by 2.8% in the second quarter. Vanguard Group Inc. now owns 93,657,300 shares of the medical equipment provider’s stock valued at $2,596,181,000 after buying an additional 2,522,556 shares during the period. Janus Henderson Group PLC increased its stake in shares of Boston Scientific Corporation by 22,491.6% in the second quarter. Janus Henderson Group PLC now owns 38,862,599 shares of the medical equipment provider’s stock valued at $1,077,270,000 after buying an additional 38,690,577 shares during the period. Finally, Winslow Capital Management LLC increased its stake in shares of Boston Scientific Corporation by 21.9% in the second quarter. Winslow Capital Management LLC now owns 11,212,783 shares of the medical equipment provider’s stock valued at $310,818,000 after buying an additional 2,011,640 shares during the period. 90.50% of the stock is owned by hedge funds and other institutional investors.
Several research firms have recently issued reports on BSX. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $31.00 price objective on shares of Boston Scientific Corporation in a research note on Tuesday, November 7th. SunTrust Banks, Inc. set a $34.00 price objective on Boston Scientific Corporation and gave the company a “buy” rating in a research note on Tuesday, October 31st. Zacks Investment Research downgraded Boston Scientific Corporation from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. BMO Capital Markets upped their price objective on Boston Scientific Corporation from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. Finally, Canaccord Genuity began coverage on Boston Scientific Corporation in a research note on Tuesday, October 24th. They issued a “buy” rating and a $36.00 price objective for the company. One research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $30.77.
Boston Scientific Corporation (BSX) opened at $28.45 on Tuesday. The stock has a market capitalization of $38,943.84, a P/E ratio of 23.25, a price-to-earnings-growth ratio of 2.19 and a beta of 1.00. Boston Scientific Corporation has a twelve month low of $19.67 and a twelve month high of $29.93. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58.
Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.31. The firm had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.60% and a net margin of 9.55%. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.27 EPS. sell-side analysts anticipate that Boston Scientific Corporation will post 1.25 earnings per share for the current fiscal year.
In other Boston Scientific Corporation news, EVP Timothy A. Pratt sold 10,104 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $27.46, for a total transaction of $277,455.84. Following the transaction, the executive vice president now directly owns 185,742 shares in the company, valued at approximately $5,100,475.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Timothy A. Pratt sold 10,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $28.22, for a total value of $282,200.00. Following the transaction, the executive vice president now owns 164,681 shares in the company, valued at $4,647,297.82. The disclosure for this sale can be found here. Insiders have sold a total of 508,864 shares of company stock worth $14,581,669 over the last 90 days. Company insiders own 0.74% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was first posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.truebluetribune.com/2017/11/14/dupont-capital-management-corp-buys-shares-of-8798-boston-scientific-corporation-bsx-2.html.
Boston Scientific Corporation Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.